Skip to search formSkip to main contentSkip to account menu

SYN-004

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Recombinant Proteinsbeta-Lactamase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
2018
2018
Sa1839 - Orally Delivered Beta-Lactamase Prevents Gut Microbiome Dysbiosis Caused by IV and Oral Antibiotics and Mitigates Propagation of Antibiotic Resistance in Porcine and Canine Models
Highly Cited
2017
Highly Cited
2017
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies
ABSTRACT SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam… 
2017
2017
SYN‐004 (ribaxamase), an oral beta‐lactamase, mitigates antibiotic‐mediated dysbiosis in a porcine gut microbiome model
To evaluate an antibiotic inactivation strategy to protect the gut microbiome from antibiotic‐mediated damage. 
2017
2017
SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
Abstract Background Clostridium difficile infections (CDI) are an “urgent threat,” but there are no approved drugs or vaccines to… 
2017
2017
SYN-004 (ribaxamase) Protects the Diversity of the Gut Microbiome in Patients Receiving Intravenous Ceftriaxone Treatment
P R I M A R Y E N D P O I N T C O N C L U S I O N S The use of intravenous β-lactam antibiotics, including cephalosporins, are an… 
2016
2016
Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1…
BackgroundSYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous… 
Highly Cited
2016
Highly Cited
2016
Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.
2016
2016
Nonclinical Safety Assessment of SYN-004
SYN-004 is a first in class, recombinant β-lactamase that degrades β-lactam antibiotics and has been formulated to be… 
2016
2016
SYN-004, A NOVEL STRATEGY TO PROTECT THE GUT MICROBIOME FROM THE DELETERIOUS EFFECTS OF RESIDUAL IV β-LACTAM ANTIBIOTICS
SYN-004 is a clinical stage oral β-lactamase therapy for use with intravenous (IV) β-lactam antibiotics to preserve the gut… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)